Other News To Note
Tuesday, August 30, 2011
NovAliX SAS, of Strasbourg, France, signed a drug discovery collaboration with Galapagos NV, of Mechelen, Belgium, in the field of osteoarthritis. Under the terms, NovAliX will handle the discovery of specific small-molecule lead candidates for a target chosen by Galapagos and then will identify hits using its Graffinity fragment-based screening technology. In exchange, NovAliX will receive technology access fees, research funding and potential milestones. Specific financial terms were not disclosed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.